NASDAQ:INCR

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

Retrieved on: 
Wednesday, May 1, 2024
Cannabis, Alternative Medicine, Natural Resources, Health, Pharmaceutical, FDA, IDF, Adjustment, GMP, Government, Growth

(NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.
  • Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
  • Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarters of profitability for InterCure5, with both Q3&Q4 2023 showing positive Adjusted EBITDA and profit from operations6.
  • Alexander Rabinovitch, CEO of InterCure Noted: "Despite extraordinary external challenges this year, InterCure showed solid performance, achieving our fifteenth straight quarter of profitability.

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

Retrieved on: 
Monday, April 1, 2024
Other Health, Banking, General Health, Cannabis, Professional Services, Pharmaceutical, Medical Devices, Natural Resources, Insurance, Alternative Medicine, Finance, Health, Annual report, Growth, Partnership, Patient, GMP, TYSON, Government, 20F, Drug

(NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023.

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023.
  • Annual revenue for 2023 is estimated at NIS 351 million, and revenue for the H2 2023 is estimated at NIS 140 million.
  • EBITDA for 2023 is estimated at over NIS 50 Million, and H2 2023’s EBITDA is estimated to reach over NIS 20 million and over 14% of revenues.
  • Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarter of profitability for InterCure, with both Q3&Q4 showing a positive EBITDA and profit from operations.

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

Retrieved on: 
Friday, March 22, 2024
Alternative Medicine, Cannabis, Health, Other Health, Natural Resources, General Health, Pharmaceutical, Narcotic, Federal republic, Cannabis Act, Patient, Drug

On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.

Key Points: 
  • On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
  • While the Cannabis Act deals with all types of cannabis, it is poised to have a uniquely significant impact on the medical cannabis sector.
  • This sets the stage for expected significant expansion of the medical cannabis market in Germany.
  • As a leader in pharmaceutical Cannabis, we are closely watching these developments including the potential rescheduling of Cannabis in the United States, and plan to advance our global footprint, expecting to launch our products in Germany in the coming months.

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Retrieved on: 
Thursday, November 17, 2022
Pharmaceutical, Health, Natural Resources, Cannabis, Good, Sale, Cannabis Act, GMP, Exercise, Partnership, News, Edible, OGI, Patient, TSX, TASE, Security (finance), Nature, Big Bag, Genetics, Transport, Term, Ministry, Cannabis, Timeline of cannabis laws in the United States, Drug, Risk management, Health, Organizational chart, Trailblazer

Organigram and InterCure entered into a previous strategic supply agreement in June 2020, (the First Strategic Agreement) that contemplated a minimum supply of 3,000 kg all of which has been fulfilled.

Key Points: 
  • Organigram and InterCure entered into a previous strategic supply agreement in June 2020, (the First Strategic Agreement) that contemplated a minimum supply of 3,000 kg all of which has been fulfilled.
  • The New Strategic Agreement contemplates up to 20,000 kg to be supplied to InterCure's international supply chain.
  • Approximately 2,800 kg has already been delivered to Canndoc from Organigram since July 2022 and credited against the total volume commitment under the New Strategic Agreement.
  • Subject to the terms and conditions of the New Strategic Agreement, Organigram has agreed to exclusively supply InterCure in Israel for the Term.

Clever Leaves Announces First Export to Israeli Partner InterCure

Retrieved on: 
Monday, July 18, 2022
Name, CEO, Patient, LinkedIn, BOCA, Diversified Specialty Institute Holdings, Inc., TASE, GLOBE, TSX, Fruit, THC, Good, NASDAQ, GMP, Industry, Sale, Company, Leaf, Growth, API, Partnership, Genetics, Drug

With this initial shipment, medical cannabis patients in Israel will now have access to Clever Leaves cannabis flower grown in its IMC-GAP equivalent cultivation facilities.

Key Points: 
  • With this initial shipment, medical cannabis patients in Israel will now have access to Clever Leaves cannabis flower grown in its IMC-GAP equivalent cultivation facilities.
  • Clever Leaves will first supply InterCure with a high THC strain followed by several other genetics that will arrive, as part of the long-term partnership agreement between the companies previously announced.
  • Israel has been a strategic market focus for Clever Leaves and InterCures position as a market leader further solidifies our plans for growth in the region.
  • Alex Rabinovitch, CEO of InterCure, said: "We're delighted to see the first fruit of our successful partnership with Clever Leaves.